Sonoma Pharmaceuticals (SNOA) Long-Term Deferred Tax (2022 - 2025)

Sonoma Pharmaceuticals' Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $458000.0 for Q4 2025.

• In Q4 2025, Long-Term Deferred Tax fell 39.74% year-over-year to $458000.0; the TTM figure through Dec 2025 stood at $458000.0 (down 39.74% YoY), while the FY2025 annual figure was $589000.0, down 48.56% from the prior year.
• Long-Term Deferred Tax was $458000.0 for Q4 2025 at Sonoma Pharmaceuticals, down from $508000.0 in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $1.1 million in Q1 2024 to a low of $458000.0 in Q4 2025.
• Historically, Long-Term Deferred Tax has averaged $817000.0 across 4 years, with a median of $849500.0 in 2022.
• The sharpest annual moves came in 2024 and 2025: Long-Term Deferred Tax increased 20.65% in 2024, then plunged 48.56% in 2025.
• A 4-year view of Long-Term Deferred Tax shows it stood at $1.1 million in 2022, then dropped by 15.34% to $922000.0 in 2023, then fell by 17.57% to $760000.0 in 2024, then slumped by 39.74% to $458000.0 in 2025.
• The last three Long-Term Deferred Tax figures came in at $458000.0 (Q4 2025), $508000.0 (Q3 2025), and $546000.0 (Q2 2025), per Business Quant data.